Toleranzia AB Company Description

Toleranzia AB (publ), a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases.

The company is primarily developing TOL2 drug candidate in clinical trial for treating myasthenia gravis, an autoimmune nerve and muscle disease.

The company also develops TOL3 drug candidate for the treatment of ANCA vasculitis, an autoimmune blood vessel disease.

In addition, it is also developing tolerogens technology, a treatment method that creates disease-specific tolerance in the immune system for treating various autoimmune diseases.

The company was incorporated in 2011 and is headquartered in Gothenburg, Sweden.

Toleranzia AB (publ)

Country	Sweden
Founded	2011
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	10
CEO	Charlotte Fribert

Contact Details

Address: Arvid Wallgrens backe 20 Gothenburg, 413 46 Sweden
Phone	46 7 63 19 98 98
Website	toleranzia.se

Stock Details

Ticker Symbol	TOL
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0007438577
SIC Code	2836

Key Executives

Name	Position
Charlotte Fribert	Chief Executive Officer and Executive Director
Ann-Sofie Taube	Chief Financial Officer
Dr. Bjorn Lowenadler Ph.D.	Chief Business Officer
Dr. Vidar Wendel-Hansen M.D., Ph.D.	Chief Medical Officer